University of North Carolina, Lineberger Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of North Carolina, Lineberger Comprehensive Cancer Center


Dr. Pecot Discusses T-VEC in Lung Cancer

April 02, 2018

Chad Pecot, MD, assistant professor, School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses talimogene laherparepvec (T-VEC; Imlygic) in the treatment of patients with lung cancer.

Dr. Weiner on Radiotherapy Trials in NSCLC

March 12, 2018

Ashley A. Weiner, MD, PhD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses clinical trials that have investigated the use of radiotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Long on Surgical Advances in NSCLC

March 10, 2018

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

Dr. Weiss on the Design of the PACIFIC Trial

March 09, 2018

Jared Weiss, MD, associate professor, School of Medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the clinical applications of the phase III PACIFIC trial in non–small cell lung cancer in the United States.

Dr. West on the Future of Treatment for Patients With Gynecologic Malignancies

February 23, 2018

Lindsay West, MD, gynecologic oncologist, University of North Carolina (UNC) Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the future of treatment for patients with gynecologic malignancies.

Dr. Barber on SCORPION Trial in Ovarian Cancer

September 06, 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses the importance of the SCORPION trial in ovarian cancer.

Dr. Barber on Neoadjuvant Chemotherapy in Ovarian Cancer

June 02, 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.